Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Pfizer

Share:
Related PFE
Schroer: Biotech Will Turn Around
The Generic Drug Battle
Tracking David Tepper's Appaloosa Management Portfolio - Q4 2015 Update (Seeking Alpha)

In a report published Monday, Jefferies & Company reiterated its Buy rating on Pfizer (NYSE: PFE), but slightly lowered its price target from $28.00 to $27.00.

Jefferies noted, “The 5% revenue miss in Q3'12 was forgiven to a degree as Lipitor phasing was partly to blame and EPS was still delivered through financial engineering. Lighter than expected Prevnar-13 and Enbrel sales were more concerning, though we now have the US launches of tofacitinib and hopefully Eliquis within the next 3-6 months to look forward to. New product launches, share repurchases and restructuring drive near term upside in our view.”

Pfizer closed on Friday at $24.16.

Latest Ratings for PFE

DateFirmActionFromTo
Feb 2016Argus ResearchMaintainsBuy
Jan 2016JefferiesMaintainsBuy
Dec 2015Atlantic EquitiesInitiates Coverage onOverweight

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!

Get Benzinga's Newsletters